Sulfated GAG Separation via DMB Precipitation for Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing mucopolysaccharidoses and kidney diseases are inefficient due to high costs, invasive procedures, and low specificity, particularly in early detection and differentiation of sulfated glycosaminoglycan (GAG) types, which hinders timely and accurate diagnosis.
Innovation Solution
A method utilizing dimethylmethylene blue (DMB) at acidic pH to selectively precipitate sulfated GAGs from biological samples, allowing for the separation of free and associated fractions, including exosomes, enabling quick, cost-effective, and sensitive analysis of GAG alterations, and subsequent protein or lipid profiling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If colorimetric methods with DMB are used to quantify total GAGs in urine, then quantification can be performed, but the methods have high false positive/negative rates and low specificity for differentiating GAG types
Solution Approach 1:
The method segments the GAG analysis into two distinct fractions: free GAGs and associated GAGs (bound to proteins, lipids, or exosomes). This segmentation is achieved through selective precipitation with cetylpyridinium chloride, which precipitates associated GAGs while leaving free GAGs in solution. Each fraction is then quantified separately using colorimetric methods, enabling both high-throughput quantification and improved specificity for differentiating GAG types and their binding states.
Solution Approach 2:
The invention introduces cetylpyridinium chloride as an intermediary reagent that selectively binds to associated GAGs, forming a precipitable complex. This intermediary enables the separation and selective quantification of associated versus free GAGs, resolving the limitation of conventional methods that cannot differentiate between these forms. The intermediary reagent acts as a bridge to achieve specific detection without requiring complex chromatographic separation.
2Measurement precision
If chromatographic methods (HPLC) are used to identify specific GAG types, then sensitivity and specificity are improved, but the cost and analysis time increase significantly
Solution Approach 1:
The method segments the complex GAG mixture into free and associated fractions through selective precipitation. This preliminary segmentation simplifies subsequent analysis by reducing the complexity of the sample matrix, allowing for faster and more cost-effective identification of specific GAG types within each fraction using simplified chromatographic or spectrophotometric methods, rather than requiring full HPLC analysis of the entire mixture.
Solution Approach 2:
The invention performs preliminary fractionation of GAGs into free and associated forms before any identification or quantification steps. This preliminary action removes the need for complex separation and identification procedures during the main analysis, significantly reducing both analysis time and cost while maintaining high specificity for identifying particular GAG types and their binding states.
3Measurement precision
If invasive procedures are used for disease diagnosis, then diagnostic accuracy may be improved, but patient comfort and ease of sampling deteriorate
Solution Approach 1:
The method extracts and analyzes GAG fractions from easily obtainable biological samples such as urine, synovial fluid, or serum. By taking out and analyzing the free and associated GAG fractions from these non-invasive or minimally invasive samples, the method achieves high diagnostic accuracy for conditions like mucopolysaccharidoses and kidney diseases without requiring invasive tissue biopsies or surgical procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method facilitates rapid, reliable, and less invasive diagnosis and prognosis of diseases associated with GAG alterations, enabling early detection and monitoring, and the identification of potential biomarkers for mucopolysaccharidoses and kidney diseases.
Implementation Method 1
A method utilizing dimethylmethylene blue (DMB) at acidic pH to selectively precipitate sulfated GAGs from biological samples
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is comprised in the field of glycobiology. In particular, it relates to a method for separating, in biological samples, the fraction bound to or associated with sulfated glycosaminoglycans (GAGs), and the applications thereof in biomedicine, such as for identifying the profile of glycoproteins or the profile of lipids bound to or associated with sulfated GAGs, detecting an alteration in the pattern of glycosylation by sulfated GAGs, identifying biomarkers for the diagnosis, for the prognosis, for monitoring the progression of a disease or of the effect of a therapy, or for identifying compounds suitable for the treatment of a disease. The invention also relates to methods for diagnosing mucopolysaccharidosis and for diagnosing and determining the prognosis of a kidney disease.